Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07054606 · ClinicalTrials.gov registry record · Phase 4

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

A Phase 4 study of Dry Eye, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
Phase 4
Development phase
104
Enrollment target
6
Study locations

NCT07054606: Completed Phase 4 study of Dry Eye, sponsored by Bausch & Lomb Incorporated.

NCT07054606 is a Phase 4 study of Dry Eye that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 104 participants, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (12% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07054606, a Phase 4 study of Dry Eye, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
Phase 4
Development phase
104 participants
Enrollment target
6
Study locations

Study Summary

Assess the impact of concomitant Miebo use while wearing contact lenses

Primary Outcome

Unabbreviated scale title: Contact Lens Dry Eye Questionnaire-8 Min: 1 Max: 37 Higher scores mean worse.

Conditions Studied

Interventions

  • DRUG Perfluorohexyloctane ophthalmic solution

Study Locations (6)

California

  • Site 101 - San Diego

Florida

  • Site 107 - Longwood

Kansas

  • Site 104 - Pittsburg

Minnesota

  • Site 102 - Medina

New York

  • Site 108 - Vestal

Ohio

  • Site 103 - Athens

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2025-07-02
Est. Completion 2025-11-03
Phase Phase 4
Bausch & Lomb Incorporated

174 total trials

What the finished NCT07054606 record still lists

NCT07054606 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 41 other Dry Eye trials with a reported enrollment target (12% higher).

The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Perfluorohexyloctane ophthalmic solution is the first listed.

NCT07054606 lists 6 locations in 6 states (California, Florida, Kansas).

Frequently Asked Questions

What is clinical trial NCT07054606 about?

NCT07054606 is a clinical study titled "A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear". Assess the impact of concomitant Miebo use while wearing contact lenses

What is the current status of trial NCT07054606?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2025-07-02. Estimated completion is 2025-11-03.

What conditions does trial NCT07054606 study?

This clinical trial studies the following conditions: Dry Eye.

What interventions are being tested in trial NCT07054606?

The interventions under investigation include: Perfluorohexyloctane ophthalmic solution (DRUG).

Who is sponsoring clinical trial NCT07054606?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07054606 being conducted?

This trial has 6 study locations across California, Florida, Kansas, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07054606's enrollment target sits among peer trials

104 10th of 41 higher than 31 of 41 other Dry Eye trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07054606, the US trial registry maintained by the National Library of Medicine. NCT07054606 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.